Date updated:04-09-2009
Each week I like to find beaten-up stocks that I believe have the potential to snap back in coming days due to a specific event driven catalyst that could either move the price higher or lower. I especially like when these stocks with near-term growth potential also qualify as solid long-term plays. And with the market down huge, there are penalty of short-term opportunities out there

-
BLUD
Immucor - $19.08
- -1.45%
- $19.37
Long ahead of earnings this week. This beaten down healthcare stock could ‘pop’ given its balance sheet, and competitive advantage as a high-growth blood regeneration company. Immucor is a $1.8 billion dollar company that has $90 million in cash and zero debt on its balance sheet. Immucor, which develops and manufactures blood typing reagents used by various hospitals and blood banks worldwide, has seen a huge explosion in business since 2003. Since 2003, net income went from just $15 million to over $60 million in 2007, while gross margins ballooned from 56.8% in 2003, to 70.5% in 2007. Revenues have more than doubled, tailing in at just $99 million in 2003 to over $225 million in 2007. Immucor, whose slogan is “I love blood”, seems like a likely target from Johnson & Johnson (JNJ), who just completed their takeover of Omrix Biopharmaceuticals, which makes liquid sealants used to control bleeding during surgery. Immucor which just reported its best quarter since it was first founded in 1982, beat analyst estimates by 5 cents per share, as it reported 1Q09 earnings of 29 cents per share. Sales rose 15% year-over-year to $73.2 million

-
DNDN
Dendreon Corporat - $27.69
- +1.80%
- $27.39
First let me preference this by saying that I have no idea where this stock is going---but here is an overview on why shares of Dendreon rallied almost 40 percent on 10x normal trading volume on Friday. On Friday, Dendreon received a ‘late-breaker’ presentation slot for the Provenge study at the American Urological Association annual meeting, April 25-30. A ‘late-breaker’ presentation at a medical meeting usually involves high profile studies, or ones of particular interest to the medical profession. Dendreon, is in the process of completing a late-stage phase III study including more than 500 men with late-stage prostate cancer who have not benefited from drugs that sharply lower testosterone. The company is banking on Provenge, which may be the first cellular immunotherapy drug for men with prostate cancer. That said, selection of studies as a late breaker is no indication whether the data will be positive or negative.

-
AA
Alcoa Inc - $13.00
- +0.62%
- $12.99
Aloca (AA): Aloca is one of the world’s largest aluminum producers accounting for almost 40 percent of the worlds aluminum produced. For the full-year 2008, Aloca earned $30.7 billion dollars in net revenue with a 15.5 percent EBITDA margin. Sales were broken down by region as follows: 55 percent came from the United States, 25 percent came from Europe, 14 percent came from Asia Pacific, and 6 percent came from other regions of the world. 2008 revenue by industry was as follows: 25 percent for direct primary use, 10 percent was turned and used into alumina, 16 percent for packaging related goods, 14 percent for industrial goods, 14 percent for aerospace, 9 percent for automobiles, and 5 percent from transit.

-
MOS
Mosaic Company (t - $55.98
- +3.48%
- $54.41
No Analysis added

-
BBBY
Bed Bath & Beyond - $37.45
- +0.54%
- $37.50
No Analysis added

-
RIMM
Research In Motio - $59.76
- +0.39%
- $59.69
No Analysis added
- Top Professional Portfolios
- 1. Fidelity Contrafund - ...
- 2. Navellier & Associ...
- 3. Calamos Advisors
- 4. Argus Management
- 5. Charlie Munger
- show all
- Top Do-It-Yourself Portfolios
- » Joseph Russell Portfolio 1
- » Albo's First Portfolio
- » Darrell Werth Portfolio 1
- » Top 5 Small-Cap Stocks: N...
- » Echo5Joker's Portfolio
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- » Renaissance Technologies
- show all
By Jonas Elmerraji Posted on Nov. 25, 2009 With Thanksgiving fast approaching, retailers have one thing on their collective minds: Black Friday. After all, the day, whi...
By Jonas Elmerraji Posted on Nov. 24, 2009 Don’t dismiss dividends right now. While stocks may have made significant strides in the rally that’s taken hold of the m...
By Roberto Pedone Posted on Nov. 24, 2009 10 Terrific Dividend Stocks: This Barron’s article highlights 10 high-quality dividend-paying stocks for investors who’re ...
By Jonas Elmerraji Posted on Nov. 23, 2009 As well as broad-based indexes have performed in the last few months, Stockpickr's weekly Rocket Stocks list has managed to d...
A. The only one I own : SLX,
too hard pick a winner out all of them
Unusually active options can often indicate that a major event in a stock is about to take place, or that unsophisticated investors (using options in lieu of leverage) are ... more
Analyst Upgrades or Estimate Increases for Nov. 25, 2009. Read more here. more
Here are the 10 stocks in the Dow Jones Industrial Average stocks with the highest yields as of the market close on June 2, 2009. more











Comments not available